Sunday, June 24
Session 1: 7:30-9:30 pm | Etiology of Atherosclerosis: Lipoproteins and other Risk Factors. |
Alan Attie, Univ of Wisconsin, Session Chair
- Helen Hobbs, Univ of Texas, Dallas
Genetics of Lipoprotein Disorders.
- James Scott, Hammersmith, UK
Dyslipidemia and the Metabolic Syndrome.
- Nobuyo Maeda, Univ of North Carolina
Mouse Models of Atherosclerosis.
- Peter Carmeliet, Univ of Leuven
Coagulation factors and other factors in plaque development
Monday, June 25
Session 2: 9am-12:30 pm | Endothelium/Lesion Initiation |
Alan Fogelman, UCLA, Session Chair
- Michael Gimbrone, Harvard
Endothelial Cell Gene Expression Profiling.
- Myron Cybulsky, Univ of Toronto
VCAM1 and NF-KappaB signaling in Lesion initiation.
- Joseph Loscalzo, Boston University
Homocysteinemia.
- Joseph Witztum, UCSD
Lipoprotein Oxidation and Atherosclerosis.
Monday, June 25
Session 3: 7:30-9:30 pm | Inflammation |
Peter Edwards, UCLA, Session Chair
- Israel Charo, UCSF
Chemokines and their receptors.
- Diana Shih, UCLA
Paraoxonase and atherogenesis
- Diana Stafforini, Univ of Utah
Inflammatory events at the vascular wall
- Yuji Matsuzawa, Osaka University
Adipose tissue-derived protein, adiponectin and atherosclerosis
- Bryan Brewer, NIH
ABCA1 Transgenic Mice
Tuesday, June 26
Session 4: 9am-12:30 pm | Foam Cell Formation/Regression |
David Hajjar, Cornell University, Session Chair
- Noriaki Kume, Kyoto University
Oxidized Lipoprotein Receptors.
- Peter Tontonoz, UCLA
Nuclear Hormone Receptors.
- Michael Hayden, University of British Columbia
Genetics of Tangier Disease.
- Edward Neufeld, NIH
Cellular Mechanisms of ABC1-mediated efflux.
- Carl Sparrow, Merck Research Laboratories
An LXR agonist induces ABCA1 and cholesterol efflux
- Robert Aiello, Pfizer
Role of macrophage ABCA1 in maintenance of HDL levels
Tuesday, June 26
Session 5: 7:30-9:30 pm | Complexity of Plaques |
Joseph Witztum, Session Chair
- Goran Hansson, Sweden
Immune mechanisms in atherogenesis
- Gerry Byrne, Univ of Wisconsin
Infection and atherogenesis
- Elaine Raines, Univ of Washington
Dynamic Regulation of Smooth Muscle Cell Responsiveness.
- Kevin Williams, Jefferson Medical College
Proteoglycans, lipoprotein retention and atherogenesis.
Wednesday, June 27
Session 6: 9am-12:30 pm | Complications of Plaques/Thrombosis. |
Peter Libby, Harvard, Session Chair
- Peter Libby, Harvard
Pathogenesis of the unstable plaque.
- Michael Rosenfeld, Univ of Washington
Animal Models of Plaque instability.
- Garrett Fitzgerald, Univ of Pennsylvania
Mouse and human models of eicosanoid metabolism.
- Karen Moulton, Harvard
Angiogenesis and atherosclerosis
Wednesday, June 27
Session 7: 7.30 pm-9.30pm | Intervention/Angiogenesis |
S. Rafii, Cornell, Session Chair
- Seppo Yla-Herttuala, Kopio, Finland
VEGF Gene Therapy
- Roger Davis, San Diego State
Developing novel gene therapies for atherosclerosis.
- Shahin Rafii, Cornell
Essential Role of bone marrow-derived endothelial and hematopoietic precursor cells in the regulation of post-natal angiogenesis and vasculogenesis.
- Margarete Mehrabian, UCLA
A genetic locus in mice that blocks atherogenesis despite hyperlipidemia
Thursday, June 28th
Session 8: 9 am-12.30pm | Genetics/Genomic Approaches |
Edward Rubin, Lawrence Berkeley National Laboratory, Session Chair
- David Cox, Stanford
Human genetic variation and cardiovascular disease
- Carrie Welch, Columbia University
Genetic Susceptibility to Athersosclerosis in Mice
- Robert Mahley, Gladstone
Genetics of Low HDL
- David Silver, Columbia University
HDL metabolism/obesity.
Thursday, June 28th
Session 9: 8-9:30 pm | Keynote Lecture |
- Edward Rubin, Lawrence Berkeley National Laboratory
The Genome Project and vascular disease
|
